Duke University Awarded Susan G. Komen Grant to Evaluate EntreMed’s PanzemÂ® NCD in Breast Cancer
PanzemÂ® NCD to be Tested in Metastatic Breast Cancer
June 29, 2005
ROCKVILLE, MD, June 29—EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, today announced that Duke University Medical Center has received a grant from the Susan G. Komen Breast Cancer Foundation to study the Company’s lead compound, 2ME2 (2-Methoxyestradiol or PanzemÂ®), in metastatic breast cancer. Basic, translational and clinical studies will be conducted using PanzemÂ® NCD in combination with a variety of chemotherapeutic agents to determine the effect of 2ME2 on chemotherapy resistant tumors. EntreMed will supply PanzemÂ® NCD for these studies.
Kimberly L. Blackwell, M.D., Director, Clinical Trials in Breast Cancer at the Duke University Medical Center commented, “Our prior studies demonstrate that the inhibition of HIF-1Î±lpha causes near-complete destruction of tumor vessels and significantly improved radio-sensitivity in radiation resistant breast tumors. We believe that the inhibition of HIF-1Î±lpha may have the same or similar impact on chemotherapy-resistant tumors. Through studies performed under this grant, we hope to determine which chemotherapy agents and HIF- 1alpha inhibiting drugs work best together.”
Breast cancer remains a significant health problem, killing over 40,000 American women annually, despite the recent introduction of new therapies. Ten-year survival rates for women receiving standard systemic therapy is 50- 80% due to insufficient response to hormonal and chemotherapy. A primary resistance mechanism is thought to be the upregulation of HIF-1Î±lpha. 2ME2 is a potent inhibitor of HIF-1Î±lpha, and its down-regulation is closely associated with 2ME2’s tubulin inhibitor properties. HIF-1Î±lpha is over- expressed in more than 70% of human tumors and HIF-1Î±lpha over-expression correlates with tumor aggressiveness, metastases and poor prognosis.
Carolyn F. Sidor, M.D., M.B.A, EntreMed Vice President and Chief Medical Officer, commented on the grant, “Tumor chemoresistance continues to be a problem in metastatic breast cancer. The Duke University studies are designed to determine if blocking HIF-1Î±lpha will overcome cancer cell resistance to standard chemotherapeutic agents. We are pleased to have the opportunity to contribute to the research effort of this leading breast cancer research team.”
Dr. Sidor further commented, “EntreMed believes that 2ME2 has the potential to be a unique cancer therapy and may be particularly well-suited to attack tumors that are dependent on the pro-angiogenic activity of HIF-1Î±lpha. PanzemÂ® NCD’s safety profile and lack of MDR chemoresistance offer opportunities for combining it with conventional chemotherapies to increase their effectiveness while decreasing toxicity. The results of the Duke studies will provide valuable information regarding the potential for PanzemÂ® NCD to complement chemotherapy.”
PanzemÂ® NCD is a novel anticancer agent, which is part of a next generation of antimitotic cancer drugs that bind to tubulin and work through multiple cellular pathways. 2ME2 can attack tumors on multiple fronts—directly by disrupting microtubules, an intracellular matrix necessary for the rapid division of cancer cells (mitosis), by inducing programmed cell death (apoptosis), and by blocking blood vessels that feed tumors (angiogenesis inhibition). EntreMed is currently evaluating 2ME2 formulations (PanzemÂ® Capsules and PanzemÂ® NCD) in Phase I and II clinical oncology studies.
EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. PanzemÂ® (2-methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development for non-oncology indications. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation and inflammation—processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under “Risk Factors,” including risks relating to the need for additional capital and the uncertainty of additional funding; the early-stage products under development; uncertainties relating to clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company’s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
CASI Pharmaceuticals, Inc.